এই এপিসোড সম্বন্ধে
Psychedelics are getting a Big Pharma moment, as Eli Lilly acquires Christian Angermayer’s AtaiBeckley for $2.8 billion, bringing its experimental psychedelic treatments—including a fast-acting 5-MeO-DMT therapy for treatment-resistant depression—under the umbrella of one of the world’s largest drugmakers. We look at why the deal matters, and whether psychedelics are finally moving into mainstream medicine.
We also break down Merck’s new cholesterol pill, enlicitide, which brings the powerful PCSK9 approach to lowering LDL into a daily pill instead of an injection. And finally: when does your smartwatch become a medical device? As wearables get better at detecting and monitoring real health conditions, the line between wellness gadget and clinical tool is starting to disappear.
